Immutep LtdASX: IMM

Excellent Overall Survival in Head & Neck Cancer Patients

· Issued by Immutep Ltd

Filed with ASX · · 2 pages · English

Summary by 6ix AI

Immutep Ltd reports excellent overall survival results for head and neck cancer patients treated with its immunotherapy Efti in combination with KEYTRUDA® (pembrolizumab). Immutep plans to meet with the FDA to discuss potential approval pathways for this treatment, highlighting the high unmet medical need in this patient population.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Immutep Ltd on 6ix

Story so far

Earlier from Immutep

Later from Immutep

All Immutep news releases